Chapter 3: Use of ESAs and other agents to treat anemia in CKD.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review.BMC nephrology · 2019
   Pooled it
2. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2015
   Pooled it
3. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.American journal of nephrology · 2018
   Trial
4. Erythropoiesis-stimulating agent hyporesponsiveness and malignancy development in patients with non-dialysis chronic kidney disease: a prospective cohort study.Clinical and experimental nephrology · 2026
   Article
5. EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report.Kidney medicine · 2025
   Article
6. Remote management of anaemia in patients with end-stage kidney disease using a wearable, non-invasive sensor.Clinical kidney journal · 2025
   Article
7. Care of Adults with Advanced Chronic Kidney Disease.Journal of clinical medicine · 2024
   Review
8. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.Clinical and experimental nephrology · 2024
   Article
9. Association Between the Polymorphism of Angiotensin-Converting Enzyme Gene and Interleukin-1 Beta Gene and the Response to Erythropoietin Therapy in Dialysis Patients with Anemia.Balkan journal of medical genetics : BJMG · 2023
   Article
10. The Resolution of a Cerebrovascular Accident With Phlebotomy in a Hemodialysis Patient With Sickle Cell Disease.Cureus · 2023
    Article
11. Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria.European journal of medical research · 2023
    Article
12. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PROKidney medicine · 2023
    Article
13. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With NonKidney medicine · 2023
    Article
14. Relationship Between the Effect of Roxadustat and Comorbid Diabetes in Non-dialyzed Chronic Kidney Disease Patients: A Retrospective Observational Study.Cureus · 2023
    Article
15. The effect of oral zinc on hemoglobin and dose of erythropoietin in hemodialysis patients.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023
    Article
16. The Influence of Iron-Deficiency Anaemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consumptions in Chronic Kidney Disease Patients Affected by IDA: A Real-Word Evidence Study among the Italian Population.Journal of clinical medicine · 2022
    Article
17. Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients.International journal of molecular sciences · 2022
    Article
18. Contemporary outcomes of anemia in US patients with chronic kidney disease.Clinical kidney journal · 2022
    Article
19. Effects of the route of erythropoietin administration on hemoglobin variability and cardiovascular events in hemodialysis patients.Kidney research and clinical practice · 2021
    Article
20. Efficacy and safety of recombinant human erythropoietin (Hema-PlusWorld journal of nephrology · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.